On May 25, 3:00 am, Alan S <loralgtweightandca...@gmail.com> wrote:On
my leukemia mailing list there are several type 2 diabetics, but I
can't recall any type 1's. <<

And  I suppose then with your .. leukemia .. you have anemia ..

Do ya .. al ..

I suppose over the last years you have been badmouthing .. me ..
you've been 'treating' this .. anemia .. ?

Like how .. describe the .. methods .. you've been told to use by your
doctor .. ?

Shouldn't take much ..

Share .. how you came to have leukemia .. AND .. type 2 diabetes ..

Did you have type 2 diabetes BEFORE you caught .. anemia .. ?

Did you have anemia .. at all .. ?

I would like to see what association I can make through the fact they
found 92% of long term diabetics have free floating iron in their
bodies.

I would like to see what association I can make to the fact they are
curing leukemia with iron chelating drugs.

Do you think there can BE .. made .. an argument / a case if you will
that .. iron is in fact the culprit in your .. case .. and the simple
removal of said iron may cure you of your .. leukemia {cites available
upon request] .. AND at the same time allow you to .. contribute ..
BY .. ?

Enrolling in the large clinical trial of iron depletion in type 2
diabetes ..

Have you heard about the trial .. ?

Mr. longtermdiabetic ..

Have you heard how diabetes is hypothesized to be treated with iron
reduction and how leukemia is cured with iron chelating drugs .. ?

Have ya .. heard .. that .. ?

Jabbour E, Kantarjian HM, Koller C, Taher A
Red blood cell transfusions and iron overload in the treatment of
patients with myelodysplastic syndromes.
Cancer 2008 Jan 10.

BACKGROUND:
Approximately 15,000 new cases of myelodysplastic syndromes (MDS) are
expected in the United States each year.
METHODS:
The mainstay for the management of myelodysplastic syndromes (MDS) is
supportive therapy with red blood cell (RBC) transfusions to improve
the patient's quality of life. RBC transfusions enable adequate
tissue
oxygenation and increase hemoglobin levels, improve fatigue, and
improve the physical and intellectual activity of patients. Up to 90%
of patients with MDS will receive RBC transfusions during the course
of their disease, and many will become chronically dependent on
transfusions to manage their anemia. These transfusions lead to an
accumulation of excess iron that, in turn, can develop into a
condition known as iron overload, causing clinical consequences like
hypertransaminasemia and cirrhosis, dilated cardiomyopathy, and
progressive dysfunction of the endocrine glands.
RESULTS:
Studies in patients with MDS have indicated that iron overload
because
of RBC transfusions was an independent, adverse prognostic factor for
overall survival (OS) and leukemia-free survival (LFS): OS and LFS
were significantly shorter in transfusion-dependent patients with MDS
than in those who were not transfusion dependent.
CONCLUSIONS:
Although the National Comprehensive Cancer Network guidelines for the
treatment of patients with MDS recommend the use of RBC transfusions
as supportive care, they further recommend that the iron burden of
transfused patients be monitored regularly and that iron chelation
therapy be considered to maintain serum ferritin levels of <1000 ng/
mL.
Cancer 2008. (c) 2008 American Cancer Society.
---------------------------------------------------------------------------­-----

<<snip>>
resulting in long-lasting transfusion-free survival
<<snip>>

Correction of anemia in a transfusion-dependent patient with primary
myelofibrosis receiving iron chelation therapy with deferasirox
(Exjade®, ICL670)
Authors: Di Tucci, Anna Angela1; Murru, Roberta1; Alberti, Daniele2;
Rabault, Bertrand2; Deplano, Simona1; Angelucci, Emanuele1

Source: European Journal of Haematology, Volume 78, Number 6, June
2007, pp. 540-542(3)

Publisher: Blackwell Publishing
Abstract:

Transfusional iron overload in patients with chronic anemias can
result in multiple organ failure. Experience in the management of
iron
overload in patients with myelodysplastic syndromes is limited, as
many do not receive chelation therapy due to short-life expectancy
and
the difficulties associated with the administration of the current
reference standard chelator, deferoxamine. There have, however, been
some reports of reduced transfusion requirement associated with
chelation therapy in patients with myelodysplastic syndromes and
myelofibrosis. Here, we discuss a patient with primary myelofibrosis
and related transfusion-dependent anemia who received chelation
therapy with the once-daily oral iron chelator, deferasirox. In
addition to the reduced iron levels, the patient demonstrated an
unexpected reduction in blood transfusion requirement, ultimately
resulting in long-lasting transfusion-free survival.
Keywords: myelofibrosis; iron overload; chelation

Document Type: Research article

DOI: 10.1111/j.1600-0609.2007.00840.x

Affiliations: 1: Unità Operativa Ematologia e Centro Trapianti
Midollo
Osseo, Ospedale Oncologico `Armando Businco', Cagliari, Italy 2:
Novartis Pharma AG, Basel, Switzerland

---------------------------------------------------------------------------­-----

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk

Yup. And I know someone in my thyroid cancer group who is diabetic, and I
think there was someone in my diabetes support group who (eons ago) had
thyroid cancer. And thyca is, if not rare, at least unusual.

Being diabetic, or having cancer, does not make you somehow immune to
getting anything else.

Maybe that person in the OP's group, or the OP himself,  just didn't *know*
that people s/he knew had either diabetes or cancer. Not everyone talks
about these things & some go to considerable efforts to hide them.
bj

Me too.